RYTM Research and Charts

RYTM - Rhythm Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-08-06 (Delayed quote data 2025-07-11)

Last 86.70	Change ⇓ -2.34 (-2.63%)	Volume 1,105,293
	Open 89.59	High 90.33	Low 86.25

8EMA (Daily) 77.16	40EMA (Daily) 66.42	50EMA (Daily) 65.30	STO (Daily) 82.347	MACD Hist (Daily) 5.677
8EMA (Weekly) 68.265	40EMA (Weekly) 58.37	50EMA (Weekly) 56.45	STO (Weekly) 74.860	MACD Hist (Weekly) 3.487


Company Profile
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.